Sponsored Links


Displaying crizotinib PowerPoint Presentations

Targeted Therapy for Metastatic NSCLC PPT

Presentation Summary : EGFR mutation BRAF mutation ALK rearrangement MEK mutation ... Crizotinib is better than chemotherapy for ALK-positive patients. 2nd Generation ALK inhibitors are ...

Source : http://sumocancer.org/documents/Targeted%20Therapy%20for%20Metastatic%20NSCLC%20(Gregory%20Riely%20MD%20PhD).pptx

Lessons From Clinical Trials of Targeted Therapies for Cancer PPT

Presentation Summary : Dumb Tumors vs. Smart Tumors Clinical Trial Implications of Biomarker-Driven Therapy Slide 17 The Crizotinib Story: How It’s Supposed to Work Crizotinib: ...

Source : http://oplinc.com/Uploaded-Files/Sledge.ppt

PowerPoint Presentation PPT

Presentation Summary : Crizotinib. AP26113. EML4-ALK-L1196M. EML4-ALK. ALK-negative cells. Drug Concentration (nM) Relative Cell Viability. Ba/F3 cells (ALK-negative) engineered to express ...

Source : http://elcon.imedex.com/ELC/2012/6373/0930_Shaw_New.pptx

PowerPoint Presentation PPT

Presentation Summary : ... JTO 2010 Rapid and dramatic tumor response in ALK+ NSCLC to crizotinib Best Percent Change from Baseline in Target Lesions % Decrease or increase from ...

Source : http://l39gg632kcb0ewpfj-sites-default-files.s3.amazonaws.com/0830%20Camidge%20v2.ppt

PowerPoint Presentation PPT

Presentation Summary : 50 YO woman with ALK+ NSCLC Treated with Crizotinib September 2011 September ... The patients had been enrolled in the International Adjuvant Lung Cancer ...

Source : http://www.aats.org/LungCancer/presentations/2012/0855%20Johnson.ppt

Therapeutic Decision Making in Advanced NSCLC: A 2012 Perspective PPT

Presentation Summary : ... (FDA-approved test) IHC RT-PCR Activity of ALK Inhibitor Crizotinib in Patients With Advanced ALK-FISH–Positive NSCLC (N = 82) Shaw AT, et al. ASCO 2011.

Source : http://s3.amazonaws.com/AdvancedNSCLC2012/CCO_Advanced_NSCLC_Decisions_2012_Slides.ppt

The first 12 months of UK diagnostic services for EGFR gene ... PPT

Presentation Summary : EGFR gene mutation testing in NSCLC Rachel Butler All Wales Molecular Genetics Laboratory ... BRAF, EML4-ALK EML4-ALK gene fusions – Crizotinib FISH (IHC, ...

Source : http://www.rcpath.org/Resources/MSPowerpoint/Dr%20R%20Butler.ppt

PowerPoint Presentation PPT

Presentation Summary : Acquired Resistance to Crizotinib in ALK FISH+ . Multiple mutations in . ALK. tyrosine kinase domain. New oncogenic driver: EGFR. and . KRAS. Loss of the . ALK ...

Source : http://www.scientificorganizingservice.com/public/M.pptx

ALK in lung cancer: Past, present, and future PPT

Presentation Summary : Mechanisms of resistance to crizotinib in ALK-positive NSCLC. Camidge, D. R. Nat Rev ClinOncol. 2012 Apr 3. What Can We Do? Summary of Crizotinib Resistance.

Source : http://cisc.twbbs.org/media/slide/3147.pptx

PowerPoint Presentation PPT

Presentation Summary : Crizotinib pretreated . Advanced . ALK-rearranged malignancies. NCT01283516. Continuous oral dosing. 21-day cycles. Dose escalation started at 50 mg/day.

Source : http://cancer.dartmouth.edu/lung_thoracic/documents/Rigas_CTOP_Retreat_2014_revised.pptx

PowerPoint Presentation PPT

Presentation Summary : ALK positive patients are sensitive to crizotinib. Significant fraction of ALK+ patients were enrolled in crizotinib trials with excellent response

Source : http://www.oncoletter.ch/fileupload/MariellaGarcia.pptx

Diapositiva 1 PPT

Presentation Summary : Patient was started on crizotinib 250 mg x 2. Case Report . 46-ys-old . light ex-smoker. woman. August 2012: Start crizotinib. After 1 month of crizotinib. Almost ...

Source : http://www.perunavitacomeprima.org/principale/convegno2013/documenti/CRINO.pptx

HSP 90 Inhibitors in Lung Cancer - Emory Winship Cancer Center PPT

Presentation Summary : Next steps Combination of Crizotinib with Hsp90 inhibitors Hsp90 inhibition in Crizotinib-resistant ALK +NSCLC Hsp90 Inhibition in NSCLC It is likely that other ...

Source : https://winshipcancer.emory.edu/media/file/Sea%20Island%202011/Thursday%206_%20Ramalingam%20%202011%20novel%20agents.ppt

TRACO - Center for Cancer Research PPT

Presentation Summary : Non-small Cell Lung Cancer Eva Szabo, MD Division of Cancer Prevention, NCI ... crizotinib- 57% RR, 33% stable disease (FDA approved) Kwak EL et al. NEJM 2010; ...

Source : http://ccr.cancer.gov/cms/Courses/filemanager.axd?mode=download&path=traco%2FNon-SCLC.508.ppt

For 24 hour support call +44 151 259 62 62 PPT

Presentation Summary : ... Personalized Medicine Shaw A T and Engelman J A JCO 2013;31:1105-1111 (A) Before crizotinib; (B) after 7 weeks of crizotinib.

Source : http://cancer.dartmouth.edu/lung_thoracic/documents/C_Tsongalis.ppt

Molecular Management of Advanced NSCLC - Imedex, LLC PPT

Presentation Summary : Crizotinib – active in ALK/ROS1 translocated patients, ? met amplification/mutated. BRAF mutations – vemurafenib, dabrafenib. Studies ongoing with specifically ...

Source : http://elcon.imedex.com/ELC/2013/6699/1000_Socinski.pptx

Sponsored Links
If you find powerpoint presentation a copyright It is important to understand and respect the copyright rules of the author.
Please do not download if you find presentation copyright.
If you find a presentation that is using one of your presentation without permission, contact us immidiately at

© XPowerPoint.com